EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of serum 5' nucleotide phosphodiesterase isoenzyme v as a tumor marker in metastatic liver cancer



Evaluation of serum 5' nucleotide phosphodiesterase isoenzyme v as a tumor marker in metastatic liver cancer



Journal of Tokyo Women's Medical College 57(1): 42-54



5'-Nucleotide phosphodiesterase isoenzyme-V (5'-NPD-V) is an isoenzyme of 5'-NPD that splits nucleic acids to release 5'-nucleotide, and moves farthest to the anodic end in polyacrylamide gel electrophoresis. The author determined serum 5'-NPD-V level in total 400 patients with malignant tumors who were divided into preoperative (or non-resected) and postoperative groups, and evaluated the diagnostic utility of 5'-NPD-V for liver metastases. The diagnostic utility of 5'-NPD-V was then compared with that of serum CEA, .beta.2-microglobulin, ribonuclease, ferritin and .alpha.-fetoprotein. Patients with liver dysfunction or jaundice were excluded from the study because they exhibited a false positive response to the test. In the preoperative group, serum 5'-NPD-V test was positive in 64.3% of the patients with liver metastasis false positive in 4.5%, and the predictive value of a positive assay, denoting the presence of liver metastases, was 60%. In the postoperative group, the figures were 84.6% and 3.9%, respectively, and the predictive value was 64.7%. When CEA was used to conjunction with 5'-NPD-V, a positive response to either of the tests was exhibited by 85.7% (preoperative) and 92.3% (postoperative) of the patients with liver metastasis. From the above findings, serum 5'-NPD-V was considered to be a useful marker for the diagnosis of liver metastasis.

(PDF 0-2 workdays service: $29.90)

Accession: 005401428

Download citation: RISBibTeXText



Related references

Clinical significance of 5'-nucleotide phosphodiesterase isoenzyme-V assay as a tumor marker. Nihon Rinsho. Japanese Journal of Clinical Medicine 48 Suppl: 934-936, 1990

Clinical study on serum 5'-nucleotide phosphodiesterase isoenzyme-V as a predictor of liver metastases in patients with gastric and colorectal cancers. Nihon Geka Gakkai Zasshi 87(8): 859-869, 1986

5'-Nucleotide phosphodiesterase isozyme-V as a marker for liver metastases in breast cancer patients. Cancer 54(9): 1788-1793, 1984

Serum lactate dehydrogenase isoenzyme 1 ld 1 as tumor marker in testicular cancer. Clinical Chemistry 33(6): 932, 1987

New abnormal isoenzyme of 5'-nucleotide phosphodiesterase in the serum of human hepatoma. International Journal of Cancer 37(6): 849-851, 1986

5'-Nucleotide phosphodiesterase isoenzyme pattern in the serum of human hepatoma. Cancer Research 33(10): 2215-2217, 1973

Serum 5'--nucleotide phosphodiesterase isozyme--V test for human liver cancer. Cancer 45(2): 209-213, 1980

5'-Nucleotide phosphodiesterase isoenzyme and hepatic cancer in NCI-Mayo Clinic panel sera. Journal of the National Cancer Institute 51(6): 2005-2006, 1973

An isoenzyme of 5'-nucleotide phosphodiesterase and alpha-fetoprotein in human hepatic cancer patient sera. Cancer Research 34(10): 2459-2463, 1974

Evaluation of 5'-nucleotide phosphodiesterase isozyme-V as a predictor for liver metastasis in breast cancer patients. Cancer 50(2): 191-196, 1982

The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy. Oncology 27(10): 1028, 1030-1028, 1030, 2014

Correlation of shed serum HER-2/neu and tumor marker CA 15-3 with response to chemotherapy for metastatic breast cancer. Breast Cancer Research & Treatment 64(1): 98, November, 2000

Elevation of serum tumor marker CA 15.3 levels as the first manifestation of metastatic breast cancer to the cavernous sinus. Journal of Neuro-Ophthalmology 18(3): 176-177, 1998

Serum ferritin and binding of serum ferritin to concanavalin A as a tumor marker in patients with primary liver cell cancer and chronic liver disease. Digestive Diseases and Sciences 27(2): 111-116, 1982

Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. Journal of Obstetrics and Gynaecology Research 30(3): 193-196, 2004